Overview of Ubrolexin

Property	Description
Active ingredient	Cephalexin and Kanamycin
Form	Intramammary Suspension (Oily Paste)
Pharmacological class	Antibacterial Agents (Cephalosporin/Aminoglycoside)
General Type	Combination Product
Origin	Semi-synthetic and Natural Product-Derived

1. Defining Ubrolexin: An Antibacterial Combination Product

Ubrolexin is fundamentally defined as a veterinary medicinal product that functions as a potent, fixed-dose combination antibacterial agent. Its distinguishing feature is its specific pharmaceutical preparation as an intramammary suspension, an oily paste strictly designed for local application and delivery. The formulation's composition is designed for targeting common susceptible bacteria.

The product's identity is founded on the strategic pairing of two chemically distinct active substances. This status as a combination product reflects the goal of providing a comprehensive therapeutic approach to address mixed bacterial populations, thereby broadening the expected antimicrobial coverage compared to single-agent options.

2. Active Ingredients and Pharmacological Classification

The composition of Ubrolexin includes the active substances Cephalexin and Kanamycin, each representing a different pharmacological group. Cephalexin is classified as a first-generation cephalosporin, which belongs to the larger family of beta-lactam antibiotics. Kanamycin is categorized as an aminoglycoside. The combination of these two drug classes is a standard pharmaceutical strategy used to enhance the overall spectrum of activity, and this approach is intended to provide synergistic effects.

3. General Purpose of the Dual-Action Formulation

The general purpose of this formulation is to achieve a robust bactericidal mode of action, meaning it is designed to kill the targeted bacteria directly and irreversibly. The combination of the two active ingredients results in a synergistic antibacterial activity that enhances the product's overall efficacy compared to either substance used alone, leading to a broadened activity spectrum. This dual-mechanism approach ensures the efficient and complete elimination of susceptible bacterial populations, which is the core benefit and therapeutic goal of the medicine.

Regulatory References

WHO AWaRe Classification for Cephalexin

What side effects are possible with Ubrolexin?

Ubrolexin: Possible side effects and safety information

The regulatory safety profile for Ubrolexin, a veterinary intramammary suspension, is primarily defined by contraindications and potential safety concerns for the human user, as adverse reactions in the target species (cattle) are officially documented as None known in regulatory texts. This designation means that standard frequency classifications, such as common or rare, are not applicable to the animal.

Key Regulatory Safety Constraints

The medicine is subject to several official safety restrictions and limitations outlined in government regulatory documents:

Hypersensitivity Contraindication: Use is contraindicated in lactating cows with a known hypersensitivity to either Cephalexin or Kanamycin, or to any substance from the penicillin or cephalosporin class due to the potential for cross-sensitivity.
Resistance Contraindication: The product is contraindicated in cases of known bacterial resistance to the active ingredients.
Population Restriction: The medicine is contraindicated for use in non-lactating cattle. Conversely, official regulatory statements indicate the product can be used in pregnant cows, as studies have shown no evidence of teratogenic effects.

Risk of Cross-Resistance

The use of the product may be associated with the development of cross-resistance to other antibiotics. Official documents list specific risks: Cephalexin has a risk of cross-resistance with other cephalosporins, and Kanamycin is known to have a risk of cross-resistance with neomycin and paromomycin.

User Safety Profile

Official labeling emphasizes the safety profile for the human user handling the product. Potential allergic reactions (hypersensitivity) following contact may occasionally be serious. Serious symptoms noted in regulatory texts include swelling of the face, lips and eyes, or difficulty in breathing.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Ubrolexin, a product containing Cefalexin and Kanamycin, is intended for veterinary use. The official regulatory documentation provides specific guidance on the lack of information regarding overdosage in the target species (cattle) and strict instructions for accidental human exposure.

Documented Overdose Profile (Target Species)

Overdose Entity	Official Regulatory Statement
Overdosage Symptoms	No available data on symptoms, emergency procedures, or antidotes in the target species.
Serious Outcomes	No available data

Immediate Action for Accidental Human Exposure

Regulatory agencies emphasize the risk of hypersensitivity reactions in humans due to the Cefalexin component. Instructions for the user mandate seeking medical attention if symptoms occur after accidental exposure:

Seek Medical Advice: If general symptoms such as a skin rash develop, medical advice should be sought, and the product label should be shown to the physician.
Urgent Medical Attention Required: More serious symptoms, including swelling of the face, lips, or eyes or difficulty in breathing, are classified as serious and require immediate urgent medical attention as stated in the official label.

Therapeutic Uses of Ubrolexin

What Ubrolexin Treats: Main Uses and Benefits

Ubrolexin is commonly used to help with the management of clinical mastitis in lactating cattle, applied across domains where additional symptomatic support is needed. Its therapeutic relevance includes its use in cases involving specific Gram-positive and Gram-negative symptomatic manifestations, such as those associated with Staphylococcus aureus and Escherichia coli. The medicine is relevant in conditions presenting with acute episodes where local inflammation is prominent.

The medicine is used for managing symptoms related to inflammatory or irritative states. It helps address symptom clusters associated with the physical manifestations of acute infection, which include udder swelling, heat, and pain, alongside the presence of abnormal milk. The use of this medicine helps ease the acute symptomatic burden and supports general well-being during symptomatic phases.

“The medicine is designed to provide specific support during the active lactation period when symptoms become noticeable.”

Ubrolexin is considered relevant in clinical settings that involve acute or unstable symptom patterns during the milking period. Its application may be part of symptomatic management in these challenging phases, which may assist with maintaining functional stability and supports the animal during episodes of heightened discomfort, contributing to patient-oriented benefits associated with the active infection.

Quick Fact: Relief for Symptoms related to Inflammatory or Irritative States

Regulatory References

Health Products Regulatory Authority (HPRA) Assessment Report

Eligibility and Restrictions for Use

Ubrolexin is an antibiotic intended for use exclusively in lactating dairy cows for the treatment of clinical mastitis. Its eligibility for use is clearly defined by regulatory documents based on the animal's physiological state and specific health condition.

Eligibility Status	Population/Condition
Allowed Use	Lactating dairy cows
Contraindicated	Non-lactating cattle
Contraindicated	Known hypersensitivity to cefalexin and/or kanamycin (the active substances) or any excipient
Contraindicated	Cases of known resistance of the causative bacteria to cefalexin and/or kanamycin
Restricted Use	Must be used only for clinical mastitis, preferably based on bacterial susceptibility testing

The medicine is specifically intended for use during the lactation period and can be used during pregnancy. The overall eligibility profile is narrow, restricted to the target species and specific condition, with formal contraindications in place to prevent use in non-lactating animals or in cases of known allergy or antimicrobial resistance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Ubrolexin, derived strictly from government regulatory documentation.

Pharmacodynamic Restrictions

The regulatory profile identifies a specific constraint regarding co-administration with other anti-infective agents. Combination with bacteriostatic antimicrobials should be avoided as a precautionary measure against potential pharmacodynamic antagonism.

No interactions involving specific enzyme systems (e.g., CYP) or drug transporters are documented in the official prescribing information, nor are there mandatory timing rules requiring separation of administration from other medicinal products.

Interaction-Related Resistance Patterns

The regulatory documents formally recognize the risk of cross-resistance as an interaction-related constraint, detailing specific relationships between the active ingredients and other antimicrobial agents.

Active Ingredient Component	Resistance Entity	Regulatory Description
Cephalexin (Cephalosporin)	Other cephalosporins	Cross-resistance is likely to occur.
Kanamycin (Aminoglycoside)	Neomycin, Paromomycin	Cross-resistance occurs.
Kanamycin (Aminoglycoside)	Streptomycin	A one way resistance is formally known.

This structure reflects the constraints documented by regulatory authorities concerning pharmacodynamic compatibility and the established links for interaction-related resistance among chemically similar medicinal product classes.

Mechanism of Action

The action of Ubrolexin is defined by a dual mechanism that results in a bactericidal effect through two distinct and complementary methods. The drug exerts its effect by simultaneously compromising the structural integrity of the bacteria and disrupting their vital internal machinery.

️ Irreversible Inhibition of Bacterial Cell Wall Synthesis

The Cephalexin component operates within the domain of cell wall integrity, specifically targeting bacterial Penicillin-Binding Proteins (PBPs) . This interaction is an irreversible covalent inhibition that prevents the cross-linking of peptidoglycan, the final, critical step in forming the bacterial cell wall. This cascade leads directly to a compromised structure, osmotic imbalance, and eventual bacterial cell lysis, a process central to the bactericidal action.

️ Disruption of Bacterial Protein Manufacturing

The Kanamycin component is relevant within the domain of protein synthesis disruption. It engages the bacterial 30S ribosomal subunit, inducing a conformational change at the A-site . This interference forces the misreading of the mRNA template, resulting in the rapid production of faulty, non-functional proteins. This mechanism severely impairs the cell’s vital processes, providing a simultaneous functional disruption that complements the cell wall mechanism.

Dosage and Administration Information

Ubrolexin's utilization is governed by a standardized, strictly defined administration protocol, emphasizing precise drug delivery and a fixed course of therapy.

Administration Route and Dose

The product is an intramammary suspension, meaning the route of administration is confined to direct infusion into the infected udder quarter of the target species. The standard administration involves delivering the full contents of one single-use syringe per infected quarter. This unit dose delivers 200 mg of Cephalexin (as monohydrate) and 100,000 I.U. of Kanamycin (as monosulphate), which represents the fixed, active regimen.

Frequency and Procedural Requirements

The treatment follows a fixed, short-term schedule. The infected quarter must be treated twice, with a non-negotiable 24-hour interval separating the first and second administration. The entire course is thus contained within this short period.

Proper use requires specific preparatory steps immediately before administration: the udder must be milked out completely, and the teat requires thorough cleaning and disinfection to maintain aseptic conditions. Furthermore, the procedure requires that the single-use syringe must be handled carefully to avoid contamination of the injector nozzle during the procedural steps, and use of the medicine is restricted solely to the indicated target population of lactating dairy cows.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ubrolexin

Evidence for Use in Clinical Mastitis

The research base for this product includes controlled field efficacy trials which were conducted in commercial settings. These studies focused on the product’s use in conditions associated with acute or disruptive episodes, specifically clinical mastitis in lactating cattle. The primary outcomes research examined were Bacteriological Cure (confirming the absence of the original disease-causing bacteria) and measurements related to outcomes linked to inflammatory or irritative states, such as udder swelling and changes in milk appearance.

The field trials research examined the outcomes was associated with this product and those was associated with comparator treatments that was observed in the studies. Studies report how symptoms evolved in the observed populations, and findings generally described patterns where treatment outcomes was associated with various pre-existing factors, including the specific type of pathogen involved and the cow’s overall health history.

Laboratory Findings and Synergistic Research

Before field trials, laboratory research was evaluated in the specific way the two active ingredients, Cephalexin and Kanamycin, was observed in combination. These included In vitro studies (meaning studies conducted outside of a living organism) that research examined the Minimum Inhibitory Concentration (MIC) and kill-kinetics against key mastitis-causing bacteria.

Laboratory research was studied for the antibacterial activity of the combination, and data show patterns related to its action when compared to the individual components. This evidence contributes to the broader evidence landscape that studies explored during the product's evaluation.

Follow-up and Duration of Study Observation

The clinical field studies was observed in a structured follow-up process to assess outcomes describing episodic or acute changes following treatment. This follow-up was typically assessed at intervals such as 16 and 25 days post-treatment.

Follow-up durations were limited to these relatively short post-treatment intervals. As a result, there is limited information for long-term outcomes that look far beyond the initial recovery period.

What the Research Indicates is Still Uncertain

Regulatory documents acknowledge that bacteriological cure rates in the field are expected to be low for chronic infections, such as those caused by Staphylococcus aureus, because of the bacteria's ability to establish persistent infection.

Furthermore, evidence quality varies across studies. The research indicates that measuring only outcomes linked to inflammatory or irritative states (such as milk appearance) may not fully reflect the Bacteriological Cure outcome measured by testing. Data for certain groups remain insufficient when attempting to draw conclusions about the impact of every potential farm- or cow-level factor on final outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ubrolexin (FAQ)

Q: Is Ubrolexin considered a prescription-only medicine?

Yes, Ubrolexin is classified under official regulatory requirements as a prescription-only veterinary medicine. The regulatory classification indicates the medicine is to be supplied by or on the instruction of a licensed professional, such as a veterinary surgeon.

Q: What is the expected length of time for Ubrolexin to start providing its effect?

Regulatory information describes the product's action as rapidly bactericidal, meaning it is designed to kill the targeted bacteria quickly. However, a specific timeline for observing full relief from the clinical condition is not quantified in the public regulatory summary.

Q: Does Ubrolexin carry any 'Black Box' warnings in the official documents?

Official regulatory documentation confirms that Ubrolexin does not carry a Black Box Warning or similar elevated safety notification. The absence of a Black Box Warning confirms the product is not associated with this elevated safety notification level.

Q: Can Ubrolexin be used by people with a known history of heart problems?

Ubrolexin is exclusively regulated and approved as a veterinary medicine for use only in lactating dairy cows. It is not approved, safe, or intended for human consumption or use.

Q: Does Ubrolexin affect a person's ability to operate machinery?

The official user safety profile warns only about the risk of hypersensitivity reactions following contact with the product. It does not contain any warnings regarding effects such as drowsiness that would impair a user's ability to operate machinery.

Q: Is Ubrolexin a controlled substance according to regulatory bodies?

Official regulatory classifications confirm that Ubrolexin is not listed as a controlled substance under relevant national schedules.

Q: Is there a known risk of physical dependence associated with Ubrolexin?

Official regulatory documents indicate no known risk of physical dependence associated with the short-term use of Ubrolexin.

Q: Does Ubrolexin require any special monitoring like blood tests when used regularly?

The official administration protocol for Ubrolexin follows a fixed, short-term schedule. Regulatory documents confirm that the protocol does not require routine follow-up monitoring with blood tests or other laboratory evaluations.

Q: Is Ubrolexin a generic drug or a branded drug?

Ubrolexin is approved under a specific Marketing Authorisation and is classified as a branded veterinary medicine.

Q: Do official sources list any specific genetic factors that might affect Ubrolexin's effectiveness?

Official regulatory documentation does not list specific genetic factors in the target species (cattle) that are known to impact the effectiveness of Ubrolexin.

Q: Is there a patient information leaflet (PIL) available for Ubrolexin?

Yes, regulatory requirements ensure that a summary of product characteristics (SmPC) and a patient information leaflet (PIL) are publicly available for Ubrolexin to provide full product details.

Q: What are the requirements for a health professional to be eligible to prescribe Ubrolexin?

Official documents specify that Ubrolexin may only be prescribed by a veterinary surgeon who is authorized and licensed within the relevant jurisdiction. This is due to its classification as a prescription-only veterinary medicine.

Q: Is it true that Ubrolexin should not be taken with alcohol?

Ubrolexin is classified as a veterinary medicine for cattle, not a human drug. Regulatory documents focused on the human user safety profile do not list any interaction with alcohol, as this profile is limited to risks like contact hypersensitivity.

Q: Are there any common over-the-counter pain relievers that interact with Ubrolexin?

Official regulatory information primarily warns against using Ubrolexin concurrently with other specific anti-infective agents known as bacteriostatic antimicrobials. Documents do not explicitly identify interactions with commonly used over-the-counter pain relievers.

Q: Are there any specific dietary restrictions mentioned for Ubrolexin?

According to the official regulatory documents, there are no specific dietary restrictions or food-related prohibitions required for the target animal during Ubrolexin administration.

Q: Can Ubrolexin be taken with commonly used supplements like multivitamins or fish oil?

Official product labeling does not list warnings or interaction concerns related to general nutritional supplements like multivitamins or fish oil. However, regulatory sources emphasize avoiding combination with certain other prescription anti-infectives (bacteriostatic antimicrobials).

Q: Are there known interactions between Ubrolexin and blood pressure medications?

The official interaction profile focuses narrowly on avoiding combination with bacteriostatic antimicrobials. Specific interaction constraints related to non-antimicrobial drug classes, such as cardiovascular or blood pressure medications, are not documented.

Q: What is the research evidence summary regarding Ubrolexin's consistency of effect?

Regulatory research summaries indicate that the outcomes of treatment may vary depending on various pre-existing factors in the animal, such as the specific type of pathogen involved. Furthermore, cure rates are observed to be low for chronic infections, such as those caused by Staphylococcus aureus.

Q: What is the safety profile of Ubrolexin compared to a placebo in clinical trials?

Regulatory research reviews confirm that field trials examined outcomes against comparator treatments. The product's overall safety profile for the target species is documented as 'None known' in official regulatory texts.

Q: What is the official guidance on what to do if a serious side effect of Ubrolexin occurs?

The official label for the human user specifies that serious hypersensitivity symptoms can occur following contact, including swelling of the face, lips, eyes, or difficulty in breathing. Official documents state that should these symptoms occur, immediate medical attention is required.

Q: Does Ubrolexin have a known interaction with cannabis or CBD products?

Official regulatory documentation does not contain specific interaction warnings related to herbal products, including cannabis or CBD products. The official warnings focus on drug-drug interactions with specific antimicrobial agents.

Q: What is the official guidance on what to do with a used, single-use syringe?

The official disposal requirements state that all waste material derived from the product, which includes the used single-use syringe, must be disposed of in accordance with local regulations. These rules ensure that proper environmental protocols are followed.

How should Ubrolexin be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documentation defines specific rules for the storage and disposal of Ubrolexin, the intramammary suspension.

Storage Requirements

Classification	Official Requirement
Temperature	Does not require any special storage conditions.
Shelf-Life	3 years, when packaged for sale.
Protection	Keep out of the sight and reach of children.
Handling	Each syringe is for single use only.

Disposal Requirements

Unused or expired Ubrolexin, along with any waste material derived from the product, must be disposed of in accordance with local requirements. This mandate ensures that proper environmental protocols are followed and that contamination is avoided, as specified by regulatory authorities.

Ubrolexin